Mitochondria that power cellular activity fragment and change shape in breast cancer cells that migrate to the brain, an adaptation that appears necessary for the cells to survive, UT Southwestern Medical Center researchers report in a study. The findings, published in Nature Cancer, could lead to novel ways to prevent brain metastases.
The American Society of Clinical Oncology has issued new clinical guidance for best treating patients with gastrointestinal cancer amidst a nationwide shortage of carboplatin and cisplatin.
Adjuvant treatment with mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in distant metastasis-free survival (DMFS) for patients with resected high-risk melanoma (stage III/IV) in a phase IIb study.
An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer.
A study demonstrated that exercise may have the power to strengthen the immune system in patients with multiple myeloma.
After four years of follow-up, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) maintained a clinically meaningful overall survival benefit versus sunitinib in the phase III CLEAR (Study 307)/KEYNOTE-581 trial of first-line treatment in patients with advanced renal cell carcinoma.
A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant invasive disease-free survival benefits in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
In the phase II PHERGain study, 95.4% of patients who followed a chemotherapy de-escalation strategy using PHERGain’s adaptive design remained cancer-free after three years of follow-up, and around 30% of patients responded to a fully chemotherapy-free regimen as part of their treatment for HER2- positive breast cancer.
An interim analysis of the ongoing DESTINY-PanTumor02 phase II trial showed that Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful and durable responses across a broad range of HER2 expressing advanced solid tumors in previously treated patients.
In the largest sequencing study to date on testicular cancer, researchers at Children’s National Hospital have identified genes that contribute to testicular germ cell tumors (TGCT), the most common cancer among young, white men.
